Why the study?
Managing HBR patients undergoing PCI for ACS remains challenging due to limited data on balancing ischemic prevention and bleeding avoidance.
Design
Literature review
Key result
Integrating CYP2C19 pharmacogenomics with short dual antiplatelet therapy or monotherapy improves safety and efficacy for high-bleeding risk patients with acute coronary syndrome.
Authors
Loading...
May warrant CYP2C19 testing to guide short DAPT in HBR ACS; extends pharmacogenomic evidence to high-bleeding-risk PCI cohorts.
Pharmacogenomic testing for CYP2C19 and individualized antiplatelet strategies like short DAPT or monotherapy may help balance ischemic and bleeding risks in HBR patients with ACS undergoing PCI.
Michailidis et al. (2026) studied this question. Integrating CYP2C19 pharmacogenomics with short dual antiplatelet therapy or monotherapy improves safety and efficacy for high-bleeding risk patients with acute coronary syndrome.